TNFSF11 and osteoporosis: For this reason, RANKL represents a pharmacological target, and denosumab is prescribed as a RANKL inhibitor for the management of osteoporosis, despite its use as well as that of other anti-osteoporotic drugs, such as bisphosphonates and calcitonin, is related to adverse effects and regular infusion appointments are required following long-term administration which may represent a discomfort for patients [8].